BT8009

ASCO-GU – Bicycle tries to put distance between itself and Seagen
EP Vantage
Thu, 02/16/23 - 10:15 am
ASCO-GU
Bicycle Therapeutics
Seagen
Padcev
urothelial cancer
BT8009
Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data
Marketwatch
Mon, 04/11/22 - 10:39 am
AACR
Bicycle Therapeutics
clinical trials
urothelial cancer
BT8009